Gaucher Disease, Type 1 Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
Verified date | May 2021 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy and safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to imiglucerase in treatment naive patients with type 1 Gaucher disease.
Status | Completed |
Enrollment | 34 |
Est. completion date | May 5, 2009 |
Est. primary completion date | May 5, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria Includes: - The patient has a documented diagnosis and clinical manifestation of type 1 Gaucher disease - The patient is at least 2 years of age. - The patient has not received treatment for Gaucher disease (investigational products, miglustat, or imiglucerase) within 12 months prior to study entry, as documented in the patient's medical history. - Female patients of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study and must have negative results to a pregnancy test performed at the time of enrollment and as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy. - The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). - The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator. Exclusion Criteria Includes: - The patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease. - The patient has received treatment with any non-Gaucher disease-related investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted. - The patient is known to be positive for human immunodeficiency virus (HIV). - The patient is known to be positive for hepatitis B and/or C. - The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study. - The patient has a significant comorbidity(ies) that might affect study data or confound the study results (e.g., malignancies, primary biliary cirrhosis, autoimmune liver disease, etc.). - The patient is unable to comply with the protocol, e.g., has a clinically relevant medical condition making implementation of the protocol difficult, has an uncooperative attitude, is unable to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator. |
Country | Name | City | State |
---|---|---|---|
Argentina | Your Health S.A. | Buenos Aires | |
India | Malabar Institute of Medical Sciences Ltd. | Calicut | Kerala |
India | All India Institute of Medical Sciences | New Delhi | |
India | KEM Hospital Research Centre | Pune | |
Israel | Shaare Zedek Medical Center | Jerusalem | |
Paraguay | Sociedad Espanola de Socorros Mutuos | Asuncion | |
Russian Federation | National Research Center for Haematology | Moscow | |
Spain | Hospital Universitario Miguel Servet | Zaragoza | |
Tunisia | La Rabta Hospital | Tunis | |
United Kingdom | The Royal Free Hospital | London | |
United States | Duke Children's Hospital & Health Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Shire |
United States, Argentina, India, Israel, Paraguay, Russian Federation, Spain, Tunisia, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. | Baseline to Month 9 | ||
Secondary | Change From Baseline to Month 9 in Platelet Counts for Each Treatment Group. | Values shown are observed change from Baseline to Month 9. | Baseline to Month 9 | |
Secondary | Change From Baseline to Month 9 in Normalized Liver Volume (Percent (%) Body Weight) for Each Treatment Group. | Values shown are observed change from Baseline to Month 9. Measured by Magnetic resonance imaging (MRI). Liver volume has been normalized for percent (%) body weight for each treatment arm. Liver size relative to body weight = (Liver volume [cubic centimeter (cc)]/Body weight [kg]*1000. | Baseline to Month 9 | |
Secondary | Change From Baseline to Month 9 in Normalized Spleen Volume (Percent (%) Body Weight) for Each Treatment Group. | Values shown are observed change from Baseline to month 9. Measured by Magnetic resonance imaging (MRI). Spleen volume was normalized for percent (%) of body weight for each treatment arm. Spleen size relative to body weight=(Spleen volume [cc]/Body weight [kg])*100. | Baseline to Month 9 | |
Secondary | Change From Baseline to Month 9 in Plasma Chitotriosidase for Each Treatment Group. | Values shown are observed change from Baseline to Month 9. Units of measure is defined as nanomole per milliliter per hour. | Baseline to Month 9. | |
Secondary | Change From Baseline to Month 9 in Plasma Chemokine (C-C Motif) Ligand 18 (CCL18) for Each Treatment Group. | Values shown are observed change from Baseline to Month 9. | Baseline to Month 9 | |
Secondary | Number of Participants Who Developed Antibody for Each Treatment Group. | Measure type is actual number of participants who developed antibodies to treatment; GA-GCB or imiglucerase. Antibody detection was based upon serum samples collected at various time points throughout the study. Serum samples were screened using an enzyme-linked immunosorbent assay (ELISA) and positive antibody confirmation was determined using a radioimmunoprecipitation assay (RIP); positive samples were also tested for enzyme neutralizing activity. Participant samples were compared to internal assay controls (positive/negative), positive samples were determined based upon individual assay criteria. | Baseline to Month 9 | |
Secondary | Time to Response- Comparison of GA-GCB and Imiglucerase on the Earliest Time to Respond as Assessed Via Hemoglobin Concentration | Time to response was defined as a = 1 g/dL improvement in hemoglobin levels relative to Baseline. Units (%) correlates to the percentage of participants who had a change of = 1 g/dL improvement in hemoglobin levels relative to Baseline during their participation in the study. | Response rate at Month 9 compared to Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00943111 -
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
|
Phase 3 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Active, not recruiting |
NCT00891202 -
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
|
Phase 3 | |
Recruiting |
NCT05253560 -
Prodromal Parkinsonian Features in GBA1 Mutation Carriers
|
||
Completed |
NCT00813865 -
A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients
|
Phase 2 | |
Completed |
NCT00433147 -
A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
|
Phase 2 | |
Completed |
NCT00635427 -
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
|
Phase 3 | |
Completed |
NCT03950050 -
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy
|
Phase 2 | |
Terminated |
NCT03746587 -
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
|
Phase 2 | |
Active, not recruiting |
NCT00358150 -
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
|
Phase 2 | |
Completed |
NCT00446550 -
A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease
|
Phase 2 | |
Recruiting |
NCT05447494 -
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
|
Phase 1/Phase 2 | |
Completed |
NCT03333447 -
Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)
|
||
Completed |
NCT04120506 -
Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)
|
Phase 4 | |
Completed |
NCT04353466 -
Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs
|
N/A | |
Completed |
NCT00430625 -
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
|
Phase 3 | |
Withdrawn |
NCT00795197 -
A Screening Study Evaluating Disease Status of Gaucher Type I Patients
|
N/A | |
Completed |
NCT00364858 -
Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
|
Phase 4 | |
Recruiting |
NCT05487599 -
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05324943 -
A Gene Therapy Study in Patients With Gaucher Disease Type 1
|
Phase 1 |